A method for preparing dapoxetine hydrochloride tablets based on dry granulation

The preparation of dapoxetine hydrochloride tablets was optimized by using a dry granulation process. By controlling the particle size of the active pharmaceutical ingredient and the moisture content of the disintegrant, the problems of unstable flowability and dissolution in the direct compression process of powder were solved, and high-speed continuous production and stable drug release were achieved.

CN123101481APending Publication Date: 2026-11-17SINOPHARM XINGSHA PHARM XIAMEN CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202611552003.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-08
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

The existing direct compression process for dapoxetine hydrochloride tablets has problems such as poor flowability of the raw drug powder, easy sticking and clogging, large fluctuations in tablet weight, and difficulty in high-speed mass production. In addition, the unstable control of the disintegrant moisture leads to fluctuations in in vitro dissolution behavior.

Method used

The dry granulation process is adopted, and by controlling the particle size of the active pharmaceutical ingredient to 85μm~160μm, the moisture content of cross-linked sodium carboxymethyl cellulose to ≤5%, and strictly controlling the premixing sequence and time of materials, the powder properties are optimized by combining dry granulation, crushing and granulation, lubricant mixing and coating, so as to achieve high-speed continuous tableting.

Benefits of technology

It solves the problems of unstable tablet weight and easy tablet cracking in the direct powder compression process, realizes high-speed continuous production, ensures the consistency and stability of intra-batch and inter-batch dissolution behavior, is suitable for industrial production, and maintains the drug release performance and stability under different conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention discloses a method for preparing dapoxetine hydrochloride tablets based on dry granulation, belonging to the field of pharmaceutical technology. The method for preparing dapoxetine hydrochloride tablets of this invention includes the following steps: S1. Raw material pretreatment; S2. Material premixing; S3. Dry granulation and rolling; S4. Crushing and sizing; S5. Granulation; S6. Lubricant mixing; S7. Tableting / coating. The method of this invention significantly improves powder flowability, bulk density, and compressibility through roller granulation, completely solving the defects of tablet weight fluctuation, cracking, and sticking in direct powder compression processes. It supports high-speed continuous production of 250,000 tablets / hour, is suitable for large-scale pharmaceutical workshops, and stabilizes dissolution behavior by limiting the particle size of the active pharmaceutical ingredient and controlling the moisture content and formulation ratio of the disintegrant. Dry molding optimizes powder properties, achieving high-speed continuous tableting while considering both rapid in vivo drug release and industrial production feasibility.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical technology, specifically relating to a method for preparing dapoxetine hydrochloride tablets based on dry granulation. Background Technology

[0002] Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor. It increases the concentration of serotonin in the synaptic cleft by inhibiting the 5-HT transporter on the presynaptic membrane, activating 5-HT2c and 5-HT1a receptors, raising the ejaculation threshold and prolonging the latency of penile motor neuron reflexes. It is clinically used to treat premature ejaculation in men and requires rapid dissolution and absorption after oral administration to take effect.

[0003] Currently, most commercially available dapoxetine hydrochloride tablets are produced using direct powder compression, which presents two major technical bottlenecks: 1. Shortcomings in the physicochemical properties of the active pharmaceutical ingredient (API): Existing technologies (such as CN113456606A) generally employ excessive micronization (D90≤50μm) to improve the dissolution rate of dapoxetine hydrochloride. However, dapoxetine hydrochloride is a Class II low-solubility drug under the BCS classification. If the particle size and excipient disintegrant are not properly controlled, excessive micronization can lead to a sharp increase in the surface energy of the API, making it prone to sticking and impaction during high-speed tableting. Furthermore, it is extremely sensitive to the moisture content of the disintegrant, resulting in large batch-to-batch dissolution fluctuations. 2. Poor industrial adaptability of the direct powder compression process: The API and excipient powders have significant differences in flowability, low bulk density, and insufficient compressibility. During high-speed tableting, problems such as excessive tablet weight fluctuations, tablet cracking, sticking and impaction, and substandard brittleness frequently occur, limiting tableting capacity and making it difficult to achieve continuous, large-scale industrial production. Summary of the Invention

[0004] To address the shortcomings of existing powder compression processes involving micronized raw materials, such as unstable tablet weight, easy cracking, tablet sticking, and inability to achieve high-speed mass production, as well as the instability of disintegrant moisture control leading to fluctuations in in vitro dissolution behavior in existing dry granulation processes, this paper proposes a method for preparing dapoxetine hydrochloride tablets based on dry granulation. This method stabilizes dissolution behavior by limiting the particle size of the active pharmaceutical ingredient and controlling the moisture content and formulation ratio of the disintegrant. Furthermore, it optimizes powder properties through dry molding, achieving high-speed continuous tableting while balancing rapid in vivo drug release and industrial-scale production feasibility.

[0005] The objective of this invention is achieved through the following technical solution: A method for preparing dapoxetine hydrochloride tablets based on dry granulation includes the following steps: S1. Raw material pretreatment: Dapoxetine hydrochloride raw material is pulverized, and the particle size distribution D90 of the raw material is 85μm~160μm; S2. Material premixing: Add the following weight parts and feeding order to the hopper mixer: 55-59 parts of cellulose-lactose → 5-6 parts of cross-linked sodium carboxymethyl cellulose → 2-3 parts of colloidal silica → 34 parts of dapoxetine hydrochloride, premix for 2-10 minutes; S3. Dry granulation and rolling: The premixed material obtained in step S2 is fed into a dry granulator. The roller pressure of the dry granulator is 30~80mbar, the roller speed is 5~20rpm, and the feed screw speed is 10~40rpm. S4. Crushing and granulating: The shaped material obtained in step S3 is fed into a crushing and granulating machine. The screen aperture of the crushing and granulating machine is 18~30 mesh. The crushing and granulating process yields dry granules with uniform particle size. S5. Particle mixing: Add the dry particles obtained in step S4 into a mixer and mix for 5~30 minutes; S6. Lubricant mixing: Add 1-2 parts of magnesium stearate to the mixed particles obtained in step S5, and continue mixing for 2-10 minutes; S7. High-speed tableting / coating: The mixture obtained in step S6 is tableted and coated. The coating material is a water-soluble film coating premix, and the coating weight gain is 3 to 5 parts by weight.

[0006] Preferably, the moisture content of the cross-linked sodium carboxymethyl cellulose in step S2 is ≤5%.

[0007] Preferably, the moisture content of the cross-linked sodium carboxymethyl cellulose in step S2 is 1.6-5.0%. Preferably, in step S3, the dry pellet mill has a roller pressure of 60 mbar, a roller speed of 10 rpm, and a feed screw speed of 20 rpm.

[0008] Preferably, the screen aperture of the pulverizer and granulator in step S4 is 20 mesh.

[0009] Preferably, by weight, the dapoxetine hydrochloride is 33.6 parts, cellulose-lactose is 57.5 parts, croscarmellose sodium is 5 parts, colloidal silica is 2.5 parts, magnesium stearate is 1.4 parts, and water-soluble film coating premix is ​​4 parts.

[0010] It is known to those skilled in the art that, all other things being equal, reducing the particle size of the active pharmaceutical ingredient (API) increases the specific surface area of ​​the API particles, thereby increasing the contact area between the drug and the dissolution medium and accelerating the dissolution rate. If the API particle size (D90) is too large, resulting in a high proportion of coarse particles, even if the tablets can completely disintegrate, the released coarse API particles have a small specific surface area and a slow dissolution rate, leading to a still low dissolution rate. Disintegrants rely on their own water absorption and swelling capacity to disintegrate tablets. If the disintegrant has excessive moisture content, it pre-absorbs a large amount of water, reducing its swelling ratio, resulting in slow and incomplete tablet disintegration. The tablets cannot be fully broken down, and a large amount of API remains trapped inside the tablet fragments, unable to contact the dissolution medium. In this case, even if the API particle size is already very small and has good dissolution potential, it cannot be utilized, and the dissolution rate remains low. Conversely, if the disintegrant has insufficient moisture content, the static electricity of the material increases, leading to uneven mixing and dispersion, large batch-to-batch fluctuations in tablet disintegration behavior, and an increase in the Relative Dissolution Scale (RSD) of the dissolution data.

[0011] Therefore, only by controlling the particle size of the active pharmaceutical ingredient (API) and the moisture content of the disintegrant within a reasonable range can the high molecular cross-linked structure of the disintegrant with appropriate moisture content retain sufficient water absorption and swelling potential. Upon contact with the dissolution medium, it can rapidly absorb water and swell, disrupting the tablet skeleton and causing the tablet to disintegrate into fine particles. This fully releases the API particles encapsulated within, exposing them to the dissolution medium and maximizing the dissolution potential brought about by the API particle size. In long-term pharmaceutical practice, the inventors discovered that during the dry granulation preparation of dapoxetine hydrochloride tablets, the moisture content of the cross-linked sodium carboxymethyl cellulose disintegrant has a significant impact on drug dissolution. Even if the API particle size D90 is greater than 50 μm (e.g., 156 μm), as long as the disintegrant moisture content is controlled at ≤5.0%, dissolution within 15 minutes is still ≥85%. However, if the moisture content exceeds the standard (7.5%), even with very fine particle sizes, dissolution will still fail.

[0012] The effective effects of this invention are as follows: 1. This invention utilizes roller granulation to significantly improve powder flowability, bulk density, and compressibility, completely resolving defects such as tablet weight fluctuations, cracking, and sticking caused by direct powder compression processes. The dry granulation method of this invention allows for an upper limit of API particle size to 160μm, greatly reducing API pulverization energy consumption and avoiding sticking problems caused by ultrafine powders. The tableting speed can reach 250,000 tablets / hour, supporting high-speed continuous production at 250,000 tablets / hour, making it suitable for large-scale pharmaceutical workshops. The moisture content of croscarmellose sodium is controlled below 5%, with a proportion of 5%~6% in the formulation, avoiding excessive moisture or insufficient dosage that could lead to delayed disintegration and decreased dissolution rate, ensuring uniform intra-batch and inter-batch dissolution behavior. Simultaneously, the dapoxetine hydrochloride raw material has a particle size D90 of 85~160μm, optimizing the dissolution surface area for poorly soluble drugs in BCS II, ensuring highly similar dissolution curves across different batches of tablets. The dry granules prepared by the method of this invention have no moisture introduced. Stability tests under accelerated, long-term, high temperature, high humidity and light conditions show that there are no significant changes in content, dissolution and related substances, and the appearance and hardness of the tablets are stable over a long period of time.

[0013] 2. The order of material addition in step S2 of this invention cannot be reversed. That is, the filler is added first, followed by the disintegrant, then the glidant, and finally the active pharmaceutical ingredient (API). First, the filler acts as the base carrier material, forming a material bed inside the mixer to provide sufficient carrier volume space. Subsequent addition of small amounts of excipients allows them to be encapsulated and diluted by the large amount of carrier material, preventing localized agglomeration. Second, the disintegrant is added and premixed thoroughly with the filler to ensure uniform dispersion within the carrier system. Adding the disintegrant later can cause localized agglomeration, resulting in inconsistent tablet disintegration and a larger dissolution RSD. Third, the glidant is added. The glidant particles are extremely fine and their function is to coat the particle surface and improve flowability. The filler and disintegrant are mixed evenly before adding the glidant, allowing the fine glidant to be evenly coated on the powder particle surface. Adding the glidant too early can cause the fine silica to encapsulate the subsequently added API. The surface of the particles hinders the contact between API and other powders, making API difficult to disperse and prone to agglomeration. Finally, the active pharmaceutical ingredient (API) is added, and a large amount of pre-mixed excipient carrier is used to dilute and disperse the API, reducing the risk of segregation and agglomeration. This feeding sequence, combined with a premixing time of 2-10 minutes, ensures uniform dispersion of all components.

[0014] 3. In step S6 of the method of the present invention, the mixing time of the lubricant is strictly controlled within 10 minutes. Mixing magnesium stearate for more than 10 minutes can easily lead to the formation of a hydrophobic film, delaying tablet disintegration. In step S4, the sieve aperture is controlled at 18-30 mesh (preferably 20 mesh), which helps to eliminate clumps and coarse particle stratification problems, and to obtain uniformly sized dry-processed granules after crushing and granulation. In step S7, a water-soluble film-coating premix is ​​used, with the coating weight controlled at 3-5 parts by weight, which can improve the appearance of the tablets, isolate moisture, and enhance storage stability.

[0015] 4. The various process steps in this invention are inseparable and synergistic, forming an indispensable whole. Only under the process conditions of this invention—namely, raw material pretreatment, material premixing, dry granulation and rolling, crushing and sizing, granule mixing, lubricant mixing, and high-speed tableting / coating—coupled with strict material premixing order and control of the active pharmaceutical ingredient particle size D90 and disintegrant moisture content, can uniform intra-batch and inter-batch dissolution behavior be achieved. Stability tests under accelerated, long-term, high-temperature, high-humidity, and light-induced conditions show no significant changes in content, dissolution rate, and related substances, and the tablet appearance and hardness remain stable over a long period. The aforementioned processes and parameters synergistically overcome the defects of powder direct compression processes, such as unstable tablet weight, easy cracking, tablet sticking, and inability to achieve high-speed mass production, while also enabling high-speed continuous tableting, thus balancing rapid drug release in vivo and the feasibility of industrial production. Detailed Implementation

[0016] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0017] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Every smaller range between any stated value or intermediate value within a stated range, and any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0018] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be obvious to those skilled in the art. This application specification and embodiments are merely exemplary.

[0019] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0020] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0021] Unless otherwise specified, all materials and reagents used in the following examples are commercially available.

[0022] The overall process of this invention is as follows: S1. Raw material pretreatment: Dapoxetine hydrochloride raw material is pulverized, and the particle size distribution D90 of the raw material is 85μm~160μm; S2. Material premixing: Add the following weight parts and feeding order to the hopper mixer: 55-59 parts of cellulose-lactose → 5-6 parts of cross-linked sodium carboxymethyl cellulose → 2-3 parts of colloidal silica → 33-34 parts of dapoxetine hydrochloride, premix for 2-10 minutes; S3. Dry granulation and rolling: The premixed material obtained in step S2 is fed into a dry granulator and rolled into a continuous dense strip. The roller pressure of the dry granulator is 30~80mbar, the roller speed is 5~20rpm, and the feed screw speed is 10~40rpm. S4. Crushing and granulating: The shaped material obtained in step S3 is fed into a crushing and granulating machine. The screen aperture of the crushing and granulating machine is 18~30 mesh. The crushing and granulating process yields dry granules with uniform particle size. S5. Particle mixing: Add the dry particles obtained in step S4 into a mixer and mix for 5~30 minutes; S6. Lubricant mixing: Add 1-2 parts by weight of magnesium stearate to the mixed particles obtained in step S5, and continue mixing for 2-10 minutes. S7. High-speed tableting / coating: The mixture obtained in step S6 is tableted and coated. The coating material is a water-soluble film coating premix, and the coating weight gain is 3 to 5 parts by weight.

[0023] Example 1: Screening test for the dosage of croscarmellose sodium formulation 1.1 Experimental formulation design The total weight of the tablet core is fixed: 100mg / tablet for 30mg specification and 200mg / tablet for 60mg specification; the variable is the proportion of croscarmellose sodium added 4% / 5% / 6%, and the amount of other excipients is constant. Commercially available control drug 1 (60mg) and control drug 2 (30mg) are set up simultaneously.

[0024] Table 1. Content of each component in the screening test of sodium croscarmellose formulation dosage.

[0025] 1.2 Preparation process (dry granulation process) design Roller pressure 60 mbar, roller speed 10 rpm, feeding screw 20 rpm, granulation screen 20 mesh, dry preparation, tableting, and coating.

[0026] 1.3 Test Data Table 2 Results of screening test for dosage of croscarmellose sodium formulation 1 (60mg specification)

[0027] Table 3 Results of screening test for sodium croscarmellose formulation dosage 2 (30mg specification)

[0028] 1.4 Experimental Conclusions The results of the screening test for the dosage of croscarmellose sodium are shown in Tables 2 and 3. The 4% croscarmellose sodium formulation had a prolonged disintegration time, low dissolution at 5 min, and an f2 of 47 for the 30 mg specification, which was not similar to the dissolution of the control drug. Crosslinked sodium carboxymethyl cellulose 5% and 6% formulations: disintegration 5-7 min, dissolution curve f2≥50 at all time points, consistent with the dissolution behavior of the reference formulation; The dry granulation process produces granules with good flowability, and both the bulk density and tap density are improved compared to the direct powder compression process. The tablet weight difference is controlled within ±3%, and the tableting speed can reach over 250,000 tablets / hour, effectively achieving the goal of high-speed tableting. Considering both cost and disintegration stability, a 5% cross-linked carboxymethyl cellulose sodium formulation is preferred.

[0029] Example 2: Moisture Limit Test of Crosslinked Sodium Carboxymethyl Cellulose 2.1 Experimental Design To address the shortcomings of existing technologies that overemphasize fineness of grinding, this invention specifically designed a disintegrant moisture gradient test to demonstrate the necessity of the synergistic effect of "moisture control" and "appropriate particle size" proposed in this invention. The optimal formulation was fixed, and four sets of variable tests were set with disintegrant moisture content of 1.6%, 2.3%, 5.0%, and 7.5%. 2.2 Test Data Table 4 Results of moisture limit test for croscarmellose sodium 1 (60mg specification)

[0030] Table 5 Results of moisture limit test for croscarmellose sodium 2 (30mg specification)

[0031] 2.3 Experimental Conclusions The results of the moisture limit test for cross-linked sodium carboxymethyl cellulose are shown in Tables 4 and 5: Moisture content > 5.0% (7.5% group): The disintegration time of the 60mg specification was prolonged to 10 min, and the dissolution at 10 / 15 min was significantly reduced, f2=38, indicating dissimilar dissolution. Moisture ≤ 5.0% (1.6% / 2.3% / 5.0%): Disintegration stable for 6-7 min, f2 ≥ 50 for all formulations, similar to the dissolution of the reference formulation; Establish internal control standards: The moisture content of croscarmellose sodium must not exceed 5.0%.

[0032] Example 3: Particle size range test of dapoxetine hydrochloride 3.1 Experimental Design With the optimal formulation fixed (60mg see formulation 2, 30mg see formulation 5), dissolution comparisons were conducted at D90 gradients of 80μm, 120μm, 135μm, and 156μm for the active pharmaceutical ingredient.

[0033] 3.2 Test Data Table 6. Results of particle size range test for dapoxetine hydrochloride 1 (60mg specification)

[0034] Table 7. Results of particle size range test for dapoxetine hydrochloride 2 (30mg specification)

[0035] 3.3 Experimental Conclusions The particle size distribution test results for dapoxetine hydrochloride are shown in Tables 6 and 7. The dissolution curves of all samples in the particle size range of 80~156μm of the active pharmaceutical ingredient had f2≥50, which was similar to that of the control drug. After mechanical pulverization, the particle size can reach about 20μm. The raw material with a D90 of 52μm is obtained after sieving. After the raw material is produced, the initial particle size after preliminary dispersion and agglomeration is about 80~170μm. Taking into account the dissolution requirements of poorly soluble drugs and the cost of industrial pulverization, the particle size control range of the raw material is narrowed to D90=85μm~160μm.

[0036] Example 4: Finished Product Stability Verification Test Strictly control the particle size of the active pharmaceutical ingredient (D90: 85μm~160μm) and the moisture content of croscarmellose sodium (not exceeding 5.0%). Prepare the formulation (same as formulation 2 and formulation 5) according to the predetermined weight ratio of raw materials and excipients. Through stability sampling tests, systematically investigate the change law of product release rate during the sampling process to clarify the stability of the release behavior.

[0037] Table 8 Results of the finished product stability verification test:

[0038] Samples were prepared using the optimal formulation and standard dry process, and subjected to multi-condition forced degradation and long-term / accelerated stability tests. The results are shown in Table 8. 1. Accelerated conditions (40℃±2℃, 75%RH±5%RH, 6 months): Dissolution rate 99%~100%, no decrease; 2. Long-term conditions (30℃±2℃, 65%RH±5%RH, 6 months): dissolution rate 98%~100%, indicators stable; 3. Forced test (60℃ high temperature, 90% high humidity, 4500lx light for 30 days): No significant changes in content, dissolution, and related substances; Conclusion: The tablets prepared by this process have good physical and chemical stability, and there is no drift in drug release behavior during long-term storage.

[0039] Stability studies showed that the release rate of dapoxetine hydrochloride tablets prepared by strictly controlling the quality of raw materials and excipients and using a dry granulation process remained stable without significant changes. The granules prepared by the dry granulation process exhibited good physical and chemical stability in both accelerated and long-term tests. The tablet appearance, hardness, and friability all met the requirements, further validating the feasibility and stability of the dry granulation process.

[0040] While specific embodiments of the present invention have been described above, those skilled in the art should understand that the specific embodiments described are merely illustrative and not intended to limit the scope of the present invention. Equivalent modifications and variations made by those skilled in the art in accordance with the spirit of the present invention should be covered within the scope of protection of the claims of the present invention.

Claims

1. A method for preparing dapoxetine hydrochloride tablets based on dry granulation, characterized in that, Includes the following steps: S1. Raw material pretreatment: Dapoxetine hydrochloride raw material is pulverized, and the particle size distribution D90 of the raw material is 85μm~160μm; S2. Material premixing: Add the following weight parts and feeding order to the hopper mixer: 55-59 parts of cellulose-lactose → 5-6 parts of cross-linked sodium carboxymethyl cellulose → 2-3 parts of colloidal silica → 33-34 parts of dapoxetine hydrochloride, premix for 2-10 minutes; S3. Dry granulation and rolling: The premixed material obtained in step S2 is fed into a dry granulator and rolled into a continuous dense strip. The roller pressure of the dry granulator is 30~80mbar, the roller speed is 5~20rpm, and the feed screw speed is 10~40rpm. S4. Crushing and granulating: The shaped material obtained in step S3 is fed into a crushing and granulating machine. The screen aperture of the crushing and granulating machine is 18~30 mesh. The crushing and granulating process yields dry granules with uniform particle size. S5. Particle mixing: Add the dry particles obtained in step S4 into a mixer and mix for 5~30 minutes; S6. Lubricant mixing: Add 1-2 parts by weight of magnesium stearate to the mixed particles obtained in step S5, and continue mixing for 2-10 minutes. S7. High-speed tableting / coating: The mixture obtained in step S6 is tableted and coated. The coating material is a water-soluble film coating premix, and the coating weight gain is 3 to 5 parts by weight.

2. The preparation method according to claim 1, characterized in that, The moisture content of the cross-linked sodium carboxymethyl cellulose in step S2 is ≤5%.

3. The preparation method according to claim 2, characterized in that, The moisture content of the cross-linked sodium carboxymethyl cellulose in step S2 is 1.6~5.0%.

4. The preparation method according to claim 1, characterized in that, The dry pellet mill described in step S3 has a roller pressure of 60 mbar, a roller speed of 10 rpm, and a feed screw speed of 20 rpm.

5. The preparation method according to claim 1, characterized in that, The screen aperture of the pulverizer and granulator described in step S4 is 20 mesh.

6. The preparation method according to claim 1, characterized in that, By weight, the dapoxetine hydrochloride is 33.6 parts, cellulose-lactose is 57.5 parts, croscarmellose sodium is 5 parts, colloidal silica is 2.5 parts, magnesium stearate is 1.4 parts, and water-soluble film coating premix is ​​4 parts.

Citation Information

Patent Citations

  • Preparation method of dapoxetine hydrochloride tablets

    CN113456606A